Top Research Highlights

Every day, JDRF leverages the expertise and innovation of distinguished researchers from across the globe to support research for life-changing treatments and ultimately a cure for type 1 diabetes (T1D). Our mission aims to serve everybody with T1D—at all ages and stages of the disease. Please enjoy reading about some of the most recent advances […]

Carol’s Legacy Continues

Carol Lurie, beloved wife, mother and grandmother, and a founder of JDRF, passed away on Friday, February 15th. Carol and her husband Erwin played a vital part in JDRF and its contributions to diabetes research, offering continual inspiration, guidance, and support working at the chapter, national, and international levels. We will miss her.

2012 Annual Report

This year, we’re celebrating 42 years of milestones in T1D research, awareness, and advocacy. This annual report turns the spotlight on 42 of the unique people, programs, and signs of progress that compel people to join JDRF.

nPOD News Update

In December 2012, a study published in The Journal of the American Medical Association reported that people with type 1 diabetes (T1D) or who are at increased risk of developing the disease have smaller pancreases than people not at risk. Researchers studied pancreases from three groups of deceased donors: individuals with T1D, those with autoantibodies […]

FDA Issues Final Artificial Pancreas Guidance

The U.S. Food and Drug Administration (FDA) announced on November 9 the issuance of its final guidance for the development of artificial pancreas systems. The guidance incorporates nearly all of JDRF’s recommendations. This news represents a milestone victory for JDRF and the type 1 diabetes (T1D) community, as the technology is viewed by medical experts […]

FDA Approves Lucentis to Treat Diabetic Macular Edema

For many people who have experienced diabetic macular edema (DME), the future looks a little clearer. On August 10, 2012, the U.S. Food and Drug Administration (FDA) approved use of the drug Lucentis for the treatment of DME. Developed by Genentech, Lucentis is the first and only FDA-approved medicine for the condition. Diabetic macular edema […]

JDRF Discusses New Treatment for Diabetic Eye Disease

Developing effective treatments for diabetic retinopathy is a key part of JDRF’s research goals. Until recently, the only treatment for diabetic macular edema was with lasers that often halted the worsening of the condition but did not improve a person’s eyesight. Now, however, a promising new treatment has emerged in the form of a drug called Lucentis (known generically as ranibizumab).